

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2	2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
PETERS WILLIAM J					Amphastar Pharmaceuticals, Inc. [AMPH]						[Director				
(Last) (First) (Middle)				3	3. Date of Earliest Transaction (MM/DD/YYYY)						7)	X_ Officer (give title below) Other (specify below) CFO, EVP & Treasurer				
C/O AMPH. PHARMAC 6TH STREE	EUTICA	LS, INC	., 1157	0			2/2	5/20)22							
	(Stre	eet)		4	. If A	mendme	ent, Date C)rigir	nal File	ed (MM/D	D/YYYY)	6. Individual	or Joint/G	roup Filing (Check Appl	icable Line)
RANCHO CUCAMONGA, CA 91730				30								X _ Form filed by One Reporting Person Form filed by More than One Reporting Person				
((City) (Sta	ate) (Zip)									roini incu by	Wiore than C	one Reporting I	CISOII	
		,	Table I -	- Non-D	erivat	tive Sec	urities Ac	guir	ed, Di	sposed o	of, or Be	eneficially Own	ed			
<u></u>			Trans. Date			3. Trans. Code (Instr. 8)		4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)		uired (A)		ties Beneficially Owned		Ownership of Indirect Beneficia	7. Nature of Indirect Beneficial Ownership	
							Code	V	Amour	(A) or (D)	Price					(Instr. 4)
Common Stock 2/25/202				2/25/2022			M		23000		\$14.95	129042		D		
Common Stock 2/25/20:				2/25/2022			S ⁽¹⁾		11000		\$27.95	118042		D		
Common Stock 2/25/202				2/25/2022			S ⁽¹⁾		12000	D	\$28.95	106042			D	
	Tak	ole II - Deri	ivative S	Securitie	s Ben	eficiall	y Owned (e.g.,	puts,	calls, wa	arrants,	options, conver	tible secu	ırities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	e	3A. Deeme Execution Date, if an		Derivativ		ve Securities d (A) or d of (D)	6. Date Exerc Expiration D				Underlying Security	Derivative Security (Instr. 5)	derivative Securities Beneficially Owned	Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	e V	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Employee Stock Option (right to buy)	\$14.95	2/25/2022		M			23000	((2)	3/26/2025	Commo Stock	n 23000	\$0	25074	D	

Explanation of Responses:

- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2021.
- (2) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Keporting Owners							
Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
PETERS WILLIAM J							
C/O AMPHASTAR PHARMACEUTICALS, INC.			CFO, EVP & Treasurer				
11570 6TH STREET			Cro, Evr & Treasurer				
RANCHO CUCAMONGA, CA 91730							

Signatures

/s/ William J. Peters 3/1/2022

**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.